These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 21269761)

  • 21. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dermal fibrosis and cutaneous necrosis after recombinant interferon-beta1a injection in a multiple sclerosis patient.
    Ozden MG; Erel A; Erdem O; Oztas MO
    J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):112-3. PubMed ID: 15649205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
    Hesse D; Sellebjerg F; Sorensen PS
    Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis.
    Amato MP; Portaccio E; Ghezzi A; Hakiki B; Zipoli V; Martinelli V; Moiola L; Patti F; La Mantia L; Mancardi GL; Solaro C; Tola MR; Pozzilli C; De Giglio L; Totaro R; Lugaresi A; Di Tommaso V; Paolicelli D; Marrosu MG; Comi G; Pellegrini F; Trojano M;
    Neurology; 2010 Nov; 75(20):1794-802. PubMed ID: 21079181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effective combination of minocycline and interferon-beta in a model of multiple sclerosis.
    Giuliani F; Fu SA; Metz LM; Yong VW
    J Neuroimmunol; 2005 Aug; 165(1-2):83-91. PubMed ID: 15958276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis.
    Healy BC; Engler D; Gholipour T; Weiner H; Bakshi R; Chitnis T
    J Neurol Sci; 2011 Apr; 303(1-2):109-13. PubMed ID: 21251671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis.
    Parry A; Corkill R; Blamire AM; Palace J; Narayanan S; Arnold D; Styles P; Matthews PM
    J Neurol; 2003 Feb; 250(2):171-8. PubMed ID: 12574947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Interferon-beta treatment for multiple sclerosis and predictors of response].
    Kohriyama T; Ochi K; Matsumoto M
    Nihon Rinsho; 2008 Jun; 66(6):1119-26. PubMed ID: 18540357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.
    Gilli F; Marnetto F; Caldano M; Sala A; Malucchi S; Di Sapio A; Capobianco M; Bertolotto A
    J Neuroimmunol; 2005 Jan; 158(1-2):195-203. PubMed ID: 15589054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR; Cadavid D; Wolansky L; Skurnick J
    Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Brazilian database on pregnancy in multiple sclerosis.
    Finkelsztejn A; Fragoso YD; Ferreira ML; Lana-Peixoto MA; Alves-Leon SV; Gomes S; Damasceno BP; Mendes MF; Salgado PR; Correa EC; Comini-Frota ER; Diniz DS; Gama PD; Kaimen-Maciel DR; Morales RR; Arruda WO; Grzesiuk AK; Khouri JM; Lopes JS; Rocha CF; Domingues R; Gonçalves MV; Lorenti MA; Parolin MK; Siquineli F; Tosta ED; Brooks JB; Gallina AS; Melges LD; Ruocco HH
    Clin Neurol Neurosurg; 2011 May; 113(4):277-80. PubMed ID: 21159421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon alfacon-1: new preparation. Basically a me-too interferon alfa.
    Prescrire Int; 2003 Jun; 12(65):95-6. PubMed ID: 12825573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients.
    Kümpfel T; Schwan M; Pollmächer T; Yassouridis A; Uhr M; Trenkwalder C; Weber F
    Mult Scler; 2007 Nov; 13(9):1138-45. PubMed ID: 17967841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant alpha-interferon therapy in multiple myeloma.
    Anand AS; Shah PM; Parikh BJ; Shah SA; Patel KM; Shukla SN; Talati SS; Patel AR
    Indian J Cancer; 1990 Dec; 27(4):203-7. PubMed ID: 2090574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
    Jacobs LD; Beck RW; Simon JH; Kinkel RP; Brownscheidle CM; Murray TJ; Simonian NA; Slasor PJ; Sandrock AW
    N Engl J Med; 2000 Sep; 343(13):898-904. PubMed ID: 11006365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: the PRISMS study.
    Oger J; Francis G; Chang P;
    J Neurol Sci; 2005 Oct; 237(1-2):45-52. PubMed ID: 16026803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study.
    Kowalzick L; Rogozinski T; Wimheuer R; Pilz J; Manske U; Scholz A; Fierlbeck G; Mohr P; Ochsendorf F; Wagner G; Gaus W; Brzoska J; Jablonska S
    Eur J Dermatol; 2002; 12(6):558-61. PubMed ID: 12459527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis.
    Leppert D; Waubant E; Bürk MR; Oksenberg JR; Hauser SL
    Ann Neurol; 1996 Dec; 40(6):846-52. PubMed ID: 9007089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
    Vartanian T; Sölberg Sørensen P; Rice G
    J Neurol; 2004 Jun; 251 Suppl 2():II25-30. PubMed ID: 15264109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of interferon beta treatment in relapsing-remitting multiple sclerosis: an Italian cohort study.
    Russo P; Paolillo A; Caprino L; Bastianello S; Bramanti P
    J Eval Clin Pract; 2004 Nov; 10(4):511-8. PubMed ID: 15482413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.